key articles
Laparoscopic radical cystectomy and extracorporeal urinary diversion
Thursday, 20 March 2008 - Laparoscopic radical cystectoprostatectomy (LRC) with different urinary diversion. Methods has shown its benefits including decreased blood loss, decreased postoperative pain, better cosmesis, and an...
Authors: Hemal et al.
Outcome of patients refusing cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer
Friday, 14 March 2008 - Herr (2007) determined the outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer.Between 1995 and 2001, 63 patients were evaluated who...
Author: Herr
Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer
Wednesday, 12 March 2008 - Hendricksen et al. (2007) studied the additive effect of either an early instillation or maintenance instillations of adjuvant intravesical epirubicin, as compared to the epirubicin "standard"...
Authors: Hendricksen et al.
Total and free prostate-specific-antigen kinetics in patients without prostate cancer undergoing radical cystoprostatectomy
Monday, 10 March 2008 - Radical cystoprostatectomy and radical prostatectomy are the two major operations to remove prostate totally and radically. Radical cystoprostatectomy is usually performed in patients with invasive bladder...
Authors: Gregorakis et al.
Outcome after radical cystectomy with limited or extended pelvic lymph node dissection
Friday, 7 March 2008 - Radical cystectomy is the standard treatment for muscle invasive bladder cancer Bilateral pelvic lymph node dissection (PLND) is a part of radical cystectomy to enhance local disease control and to improve...
Authors: Dhar et al.
Prognostic Value of MET, RON and Histoprognostic Factors for Urothelial Carcinoma in the Upper Urinary Tract
Thursday, 6 March 2008 - RON (recepteur d'origine Nantais) (Santa Cruz Technology, Santa Cruz, California) and c-met (Dako, Glostrup, Denmark) are members of the c-met proto-oncogene family. c-met encodes a receptor tyrosine...
Authors: Comperat et al.
Combination of celecoxib with bacillus Calmette-Guerin immunotherapy against bladder cancer
Monday, 3 March 2008 - Prostaglandin E2 (PGE2) is a potent immune modulator and known to suppress both tumour antigen-specific helper T (TH1) cells and the generation of cytotoxic T lymphocytes (CTLs). Dovedi et al. (2008)...
Authors: Dovedi et al.
Muscle-invasive bladder cancer: radical cystectomy or organ sparing?
Friday, 29 February 2008 - Pro and counter arguments were presented on the topic of muscle-invasive bladder cancer (BC) during the 5th European Society of Oncological Urology (ESOU) meeting with George Thalmann arguing for...
By: Joel Vega
Nomograms for Bladder Cancer
Friday, 22 February 2008 - Patients with bladder cancer face a variable risk of recurrence based on their clinical characteristics and the biology of their disease. Physicians need tools to accurately estimate the risk of...
Authors: Shariat et al.
Schedule and duration of intravesical chemotherapy for non-muscle-invasive bladder cancer patients
Wednesday, 20 February 2008 - Optimal schedule and duration of Intravesical chemotherapy are unknown. Sylvester et al. (2008) determined the effect of schedule and duration of intravesical chemotherapy on recurrence in patients...
Authors: Sylvester et al.
